口语化疾病名称向国际规范疾病术语集的映射研究

目的：研究患者口语化疾病名称到术语疾病名称的映射，解决在线口语化疾病名称难以有效利用的问题。方法：抓取“微医网”上患者口语中的疾病名，将PubMed摘要、百度搜索页摘要与百科内容作为语料，训练词向量，用余弦距离计算相似度，由2名具有临床知识和从业经验的编码人员对结果的准确性进行检验。结果：将最相似词条的参数TopN设置为>= 30的时候效果比较好，映射到大类和细类的准确性分别稳定在60%和70%左右。结论：利用词向量将口语化疾病名称映射到国际疾病术语集，具有较强的通用性和可行性，对于在线问诊、智能分诊甚至自动化编码具有明显的参考借鉴价值。     

Sleep quality and disease activity in patients with inflammatory bowel disease: a systematic review and meta-analysis

Short sleep or insufficient sleep are significant health concerns among patients with inflammatory bowel disease (IBD). Although an association between sleep quality and disease activity has been reported, findings have been inconsistent. The aim of this systematic review and meta-analysis was to assess the association between sleep quality and disease activity in IBD patients by reviewing findings from cross-sectional and prospective cohort studies. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a systematic search was conducted in five electronic databases from inception to May 2020. Studies that examined the relationship between sleep quality and disease activity in IBD patients were screened for eligibility. Six studies were included for the analysis. Sleep quality was measured using subjective questionnaires in six studies and objective methods in three studies. Disease activity was diagnosed following standard guidelines. A significant association between subjective sleep quality and disease activity was observed (pooled OR = 3.52, 95%CI:1.82,6.83, P < 0.001). A significant association between sleep efficiency and disease activity was observed as well (pooled OR = 4.55, 95%CI:1.92,10.75, P = 0.001). Findings from this study indicate that both subjective and objective poor sleep quality were associated with an increased risk for disease activity. Larger studies with an experimental design are warranted to confirm the effects of sleep quality on intestinal pathological changes in IBD patients.     

Consensus summary report for CEPI/BC March 12–13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines

A novel coronavirus (CoV), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late 2019 in Wuhan, China and has since spread as a global pandemic. Safe and effective vaccines are thus urgently needed to reduce the significant morbidity and mortality of Coronavirus Disease 2019 (COVID-19) disease and ease the major economic impact. There has been an unprecedented rapid response by vaccine developers with now over one hundred vaccine candidates in development and at least six having reached clinical trials. However, a major challenge during rapid development is to avoid safety issues both by thoughtful vaccine design and by thorough evaluation in a timely manner. A syndrome of “disease enhancement” has been reported in the past for a few viral vaccines where those immunized suffered increased severity or death when they later encountered the virus or were found to have an increased frequency of infection. Animal models allowed scientists to determine the underlying mechanism for the former in the case of Respiratory syncytial virus (RSV) vaccine and have been utilized to design and screen new RSV vaccine candidates. Because some Middle East respiratory syndrome (MERS) and SARS-CoV-1 vaccines have shown evidence of disease enhancement in some animal models, this is a particular concern for SARS-CoV-2 vaccines. To address this challenge, the Coalition for Epidemic Preparedness Innovations (CEPI) and the Brighton Collaboration (BC) Safety Platform for Emergency vACcines (SPEAC) convened a scientific working meeting on March 12 and 13, 2020 of experts in the field of vaccine immunology and coronaviruses to consider what vaccine designs could reduce safety concerns and how animal models and immunological assessments in early clinical trials can help to assess the risk. This report summarizes the evidence presented and provides considerations for safety assessment of COVID-19 vaccine candidates in accelerated vaccine development.     

"肺炎1号"治疗新型冠状病毒肺炎451例多中心临床研究

目的:观察“肺炎1号”治疗新型冠状病毒肺炎的临床疗效。方法:选取2020年2月17日至2020年3月15日湖北省中医院、监利县中医院、蕲春县人民医院、潜江市中医院、洪湖市中医医院、阳新县中医医院、浠水县中医院、大冶市中医医院、汉川市人民医院、武昌方舱医院收治的新型冠状病毒肺炎患者451例,采用“肺炎1号”联合西医常规治疗,观察“肺炎1号”对新型冠状病毒肺炎患者的临床症状、舌象、实验室检查结果及肺部CT情况。结果:共纳入451例患者,其中轻型21例,普通型378例,重型46例,危重型6例。疑似病例6例(1.33%),临床诊断病例168例(37.25%),确诊病例277例(61.42%)。治疗后与治疗前比较,患者发热、咳嗽、乏力主要症状发生率显著降低(P<0.05);恶寒、鼻塞、流涕、打喷嚏、咽部痒、咽痛、呼吸困难、胸闷、肌肉酸痛或关节疼痛、头晕头痛、纳差、恶心呕吐、腹胀、大便稀溏症状发生率显著改善(P<0.05);白细胞计数、中性粒细胞绝对值变化差异无统计学意义(P>0.05);淋巴细胞绝对值明显升高,差异有统计学意义(P<0.05);C反应蛋白、降钙素原明显降低,差异有统计学意义(P<0.05)。退热时间3(1～3.25)d。229例患者舌质由红或绛逐渐转为淡红,好转率为75.58%;177例患者白腻苔、厚腻苔、黄腻苔明显变薄,好转率为65.31%。新型冠状病毒核酸转阴时间为8(5,11)d。415例(92.02%)肺部CT明显好转,主要表现在病灶面积减小,变薄变淡。达到出院标准430例,临床治愈率95.34%;好转15例;无效3例;死亡3例(0.67%)。治疗过程中,未见明显不良反应,临床应用安全。结论:“肺炎1号”结合西医常规治疗对新型冠状病毒肺炎有较好的治疗作用,能够快速稳定病情,阻断轻型、普通型向重型、危重型转化;明显改善患者临床症状;较好促进肺部炎性反应吸收;使用安全可靠。